Joint Study By Rosetta Genomics And NYU Langone Medical Center Identifies Potential MicroRNA Drug Target For Mesothelioma
Links shared publicly online about this topic.
- 1,141total visits
Joint Study By Rosetta Genomics And NYU Langone Medical Center Identifies Potential MicroRNA Drug Target For Mesothelioma
Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announced today that the results of a joint study with the NYU Langone Medical Cent
View full resource at medicalnewstoday.com
Most Recently Shared on May 26, 2010 at 4:06 am By:
Joint Study By Rosetta Genomics And NYU Langone Medical Center Identifies Potential MicroRNA Drug Target For Mesothelioma http://mnt.to/3D4Q
Advertisement
